Abstract
The costs of radical prostatectomy and radiation therapy for localized carcinoma of the prostate are well known, the costs of terminal care for men with metastatic disease less so. We sought to determine the costs of terminal care incurred with prostate cancer in the last year of life. A retrospective chart review was conducted at five military medical centers identifying 32 patients who had died from prostate cancer from 1995 to 1997. The data investigated were: duration of metastatic disease, days hospitalized in the last year of life, palliative procedures (surgery or radiation), chemotherapy and need for transfusions. The mean duration of symptomatic metastatic disease was 3.4 y. The mean duration of hospitalization in the last year of life was 19 days. Seven patients (22%) required channel transurethral resection of the prostate (TURP). Three patients (9%) required either percutaneous nephrostomies or stenting. The mean number of transfusions required was 5.4. Eighteen patients (56%) underwent bilateral simple orchiectomy (BSO), 14 (44%) used LHRH agonists and 11 (34%) used anti-androgens. The mean total cost of hospitalization, studies, outpatient visits to physicians, palliative procedures and hormonal therapy was $24 660 in the last year of life. Comparatively, the cost of radical prostatectomy is $12 250 and three-dimensional conformal radiation therapy is $13 823. Our estimation of costs due to metastatic disease is at best an underestimation. Men dying of prostate cancer incur significant costs in the last year of life. Based upon recent epidemiological data the cost of death due to prostate cancer in the US is over three quarters of a billion dollars a year.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Greenlee RT, Hill-Harmon MB, Murray T, Thun M . Cancer Statistics 2001 Ca: Cancer J Clin 2001 51: 15–38
Labrie F et al. Combination and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality J Clin Endocrin Metab 1995 80: 2002–2013
Litwin MS et al. Cost-efficent radical prostatectomy with a clinical care path J Urol 1996 155: 989–993
Aus G, Hugosson J, Norlen L . Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent J Urol 1995 154: 466–469
Otnes B, Harvei S, Fossa SD . The burden of prostate cancer from diagnosis until death Br J Urol 1995 75: 587–594
Carlsson P, Hjertberg H, Jonsson B, Varenhorst E . The cost of prostatic cancer in a defined population Scan J Urol Neph 1989 23: 93–96
Hugosson J, Aus G, Norlen L . Surveillance is not a viable and appropriate treatment option in the management of localized prostate cancer Urol Clin North Am 1996 23: 557–573
Beemsterboer PM et al. Advanced prostate cancer: course, care and cost implications Prostate 1999 40: 97–104
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Piper, N., Kusada, L., Lance, R. et al. Adenocarcinoma of the prostate: an expensive way to die. Prostate Cancer Prostatic Dis 5, 164–166 (2002). https://doi.org/10.1038/sj.pcan.4500565
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500565
Keywords
This article is cited by
-
Desquamation is a novel phenomenon for collective prostate epithelial cell deletion after castration
Histochemistry and Cell Biology (2014)
-
Cost Effectiveness of Risk-Prediction Tools in SelectingPatients for Immediate Post-Prostatectomy Treatment
Molecular Diagnosis & Therapy (2009)
-
Radikale Prostatektomie bei Männern unter 56 Jahren mit Prostatakarzinom
Der Urologe (2005)